Oral cavity mucoepidermoid carcinoma
disease diseaseOn this page
Also known as mucoepidermoid carcinoma of oral cavitymucoepidermoid carcinoma of the oral cavityoral cavity mucoepidermoid cancer
Summary
Oral cavity mucoepidermoid carcinoma (MONDO:0044964) is a cancer and 17 clinical trials. Top therapeutic interventions include erlotinib hydrochloride, edodekin alfa, and hpph. A subtype of mucoepidermoid carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 17
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | oral cavity mucoepidermoid carcinoma |
| Mondo ID | MONDO:0044964 |
| NCIT | C8177 |
| UMLS | C0280309 |
| MedGen | 83629 |
| GARD | 0025926 |
| Anatomy (UBERON) | UBERON:0000167 |
| Is cancer (heuristic) | yes |
Also known as: mucoepidermoid carcinoma of oral cavity · mucoepidermoid carcinoma of the oral cavity · oral cavity mucoepidermoid cancer · oral cavity mucoepidermoid carcinoma
Disease family
This is a subtype of mucoepidermoid carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › mucinous adenocarcinoma › mucoepidermoid carcinoma › oral cavity mucoepidermoid carcinoma
Related subtypes (11): trachea mucoepidermoid carcinoma, thymic mucoepidermoid carcinoma, mucoepidermoid breast carcinoma, extrahepatic bile duct mucoepidermoid carcinoma, cutaneous mucoepidermoid carcinoma, lacrimal gland mucoepidermoid carcinoma, mucoepidermoid esophageal carcinoma, laryngeal mucoepidermoid carcinoma, pulmonary mucoepidermoid carcinoma, thyroid gland mucoepidermoid carcinoma, paranasal sinus mucoepidermoid carcinoma
Subtypes (2): floor of mouth mucoepidermoid carcinoma, salivary gland mucoepidermoid carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 17.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 8 |
| Not specified | 5 |
| PHASE1/PHASE2 | 2 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00101348 | PHASE1/PHASE2 | COMPLETED | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer |
| NCT00492089 | PHASE2 | COMPLETED | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
| NCT01806675 | PHASE1/PHASE2 | COMPLETED | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
| NCT02123511 | PHASE2 | COMPLETED | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy |
| NCT00004074 | PHASE1 | COMPLETED | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
| NCT00023959 | PHASE1 | COMPLETED | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer |
| NCT00030498 | PHASE1 | COMPLETED | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
| NCT00031681 | PHASE1 | COMPLETED | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
| NCT00089362 | PHASE1 | COMPLETED | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors |
| NCT00397384 | PHASE1 | COMPLETED | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
| NCT00470496 | PHASE1 | COMPLETED | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer |
| NCT01637194 | PHASE1 | COMPLETED | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer |
| NCT01473784 | Not specified | RECRUITING | Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck |
| NCT00068497 | Not specified | COMPLETED | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer |
| NCT01155609 | Not specified | COMPLETED | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer |
| NCT01164566 | Not specified | TERMINATED | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy |
| NCT01254734 | Not specified | TERMINATED | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ERLOTINIB HYDROCHLORIDE | 4 | 3 |
| EDODEKIN ALFA | 2 | 1 |
| HPPH | 2 | 1 |
| LYSINE | 2 | 1 |
| UCN-01 | 2 | 1 |
| ALVESPIMYCIN HYDROCHLORIDE | 1 | 1 |
| CHEMBL1236539 | 0 | 1 |
Related Atlas pages
- Drugs: Erlotinib